33 related articles for article (PubMed ID: 18567668)
1. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Haugen BR; Alexander EK; Bible KC; Doherty GM; Mandel SJ; Nikiforov YE; Pacini F; Randolph GW; Sawka AM; Schlumberger M; Schuff KG; Sherman SI; Sosa JA; Steward DL; Tuttle RM; Wartofsky L
Thyroid; 2016 Jan; 26(1):1-133. PubMed ID: 26462967
[TBL] [Abstract][Full Text] [Related]
2. Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.
van der Horst-Schrivers AN; Sluiter WJ; Muller Kobold AC; Wolffenbuttel BH; Plukker JT; Bisschop PH; de Klerk JM; Al Younis I; Lips P; Smit JW; Brouwers AH; Links TP
PLoS One; 2015; 10(3):e0120184. PubMed ID: 25793762
[TBL] [Abstract][Full Text] [Related]
3. Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level.
Hänscheid H; Verburg FA; Biko J; Diessl S; Demidchik YE; Drozd V; Reiners C
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1296-302. PubMed ID: 21461735
[TBL] [Abstract][Full Text] [Related]
4. The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.
Verburg FA; Lassmann M; Mäder U; Luster M; Reiners C; Hänscheid H
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):673-80. PubMed ID: 21210115
[TBL] [Abstract][Full Text] [Related]
5. Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?
Salvatori M; Perotti G; Giovanella L; Dottorini ME
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):1039-40; author reply 1041-2. PubMed ID: 20309685
[No Abstract] [Full Text] [Related]
6. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.
Verburg FA; Stokkel MP; Düren C; Verkooijen RB; Mäder U; van Isselt JW; Marlowe RJ; Smit JW; Reiners C; Luster M
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):276-83. PubMed ID: 20091165
[TBL] [Abstract][Full Text] [Related]
7. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.
Sawka AM; Brierley JD; Tsang RW; Thabane L; Rotstein L; Gafni A; Straus S; Goldstein DP
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):457-80, x. PubMed ID: 18502337
[TBL] [Abstract][Full Text] [Related]
8. [Prospective therapy study in differentiated thyroid carcinoma].
Gemsenjäger E; Heitz P; Martina B
Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.
Pluijmen MJ; Eustatia-Rutten C; Goslings BM; Stokkel MP; Arias AM; Diamant M; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2003 Apr; 58(4):428-35. PubMed ID: 12641625
[TBL] [Abstract][Full Text] [Related]
11. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid.
Randolph GW; Daniels GH
Thyroid; 2002 Nov; 12(11):989-96. PubMed ID: 12490076
[TBL] [Abstract][Full Text] [Related]
12. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
13. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
[TBL] [Abstract][Full Text] [Related]
14. The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies.
Verkooijen RB; Verburg FA; van Isselt JW; Lips CJ; Smit JW; Stokkel MP
Eur J Endocrinol; 2008 Sep; 159(3):301-7. PubMed ID: 18567668
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
